Literature DB >> 8982772

Plasmodium falciparum-specific T cell clones from non-exposed and exposed donors are highly diverse in TCR beta chain V segment usage.

A H Fell1, S L Silins, N Baumgarth, M F Good.   

Abstract

Humans lacking previous exposure to Plasmodium falciparum typically have a high frequency of malaria-reactive T cells in peripheral blood, which cross-react with antigens from other microorganisms. We studied a large number of malaria-specific human T cell clones from non-exposed and malaria-exposed donors to determine whether this response is oligoclonal, and might therefore be generated by a limited number of cross-reactive epitopes. Most clones responded well to schizont antigen from three antigenically distinct stocks of P. falciparum. Clones derived from the same donor tended to show similar patterns of reactivity to a panel of non-malaria antigens from various microorganisms, suggesting that a limited number of epitopes were recognized by individuals. However, analysis of the usage of V segments of the beta chain of the TCR (TCRBV) revealed no evidence of TCRBV restriction in the T cell response, either within individual donors or across all donors. An apparent skewing towards TCRBV8 in one donor was shown by two methods to be due to in vitro expansion of a single clone: (i) Direct sorting of TCRBV8+ CD4+ T cells from fresh PBMC did not reveal any enrichment for pRBC-reactive cells; (ii) Sequencing of VDJ regions revealed that the TCRBV8 clones were identical. Sequences of non-TCRBV8 clones from this donor showed major differences in the VDJ junctional region. No differences in TCRBV repertoire between non-exposed and exposed donors were observed. These results exclude the existence of a malarial superantigen and suggest that the T cell response to malaria schizont antigen in non-exposed donors is driven by a large number of epitopes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982772     DOI: 10.1093/intimm/8.12.1877

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  5 in total

1.  Deletion of Plasmodium berghei-specific CD4+ T cells adoptively transferred into recipient mice after challenge with homologous parasite.

Authors:  C Hirunpetcharat; M F Good
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

2.  Atypical activation of dendritic cells by Plasmodium falciparum.

Authors:  Anton Götz; Mei San Tang; Maureen C Ty; Charles Arama; Aissata Ongoiba; Didier Doumtabe; Boubacar Traore; Peter D Crompton; P'ng Loke; Ana Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-21       Impact factor: 11.205

3.  The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection.

Authors:  Huji Xu; Jiraprapa Wipasa; Huaru Yan; Ming Zeng; Morris O Makobongo; Fred D Finkelman; Anne Kelso; Michael F Good
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

Review 4.  The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development.

Authors:  Wilson L Mandala; Visopo Harawa; Fraction Dzinjalamala; Dumizulu Tembo
Journal:  Mol Biochem Parasitol       Date:  2021-10-16       Impact factor: 1.759

5.  Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.

Authors:  Cindy Tamminga; Martha Sedegah; Santina Maiolatesi; Charlotte Fedders; Sharina Reyes; Anatalio Reyes; Carlos Vasquez; Yolanda Alcorta; Ilin Chuang; Michele Spring; Michael Kavanaugh; Harini Ganeshan; Jun Huang; Maria Belmonte; Esteban Abot; Arnel Belmonte; Joglenna Banania; Fouzia Farooq; Jittawadee Murphy; Jack Komisar; Nancy O Richie; Jason Bennett; Keith Limbach; Noelle B Patterson; Joseph T Bruder; Meng Shi; Edward Miller; Sheetij Dutta; Carter Diggs; Lorraine A Soisson; Michael R Hollingdale; Judith E Epstein; Thomas L Richie
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.